This inventor holds 1 USPTO granted patent. Top assignee: American Foundation for Biological Research, Inc.. Active years: 2002.
Company Filing History:
Years Active: 2002
Title: The Innovative Contributions of Serguei Zoubak in Cancer Immunotherapy
Introduction
Serguei Zoubak is a notable inventor based in Germantown, MD (US), recognized for his significant contributions to the field of cancer immunotherapy. His innovative approach focuses on the use of truncated tumor or tumor-associated antigens to enhance treatment efficacy while minimizing side effects.
Latest Patents
Serguei Zoubak holds a patent for "Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen." This patent involves DNA constructs for truncated forms of cancer-specific or cancer-associated antigens included in plasmid or viral expression vectors. The rationale behind using truncated constructs is to eliminate side effects such as toxicity and signal transduction that arise from expressed proteins. The extracellular portion of the human prostate-specific membrane antigen (XC-PSMA) has been cloned, and patients have been treated using various methods, including injections of DNA coding for XC-PSMA and exposure of dendritic cells to plasmid or adenovirus.
Career Highlights
Serguei Zoubak is affiliated with the American Foundation for Biological Research, Inc., where he continues to advance research in cancer treatment. His work has shown promising results, with some patients experiencing a retardation or cessation of metastatic prostate cancer progression.
Collaborations
Throughout his career, Zoubak has collaborated with notable colleagues, including Milcho S Mincheff and Dmitri Loukinov, contributing to the advancement of cancer immunotherapy research.
Conclusion
Serguei Zoubak's innovative work in cancer immunotherapy exemplifies the potential of using truncated antigens to improve treatment outcomes. His contributions are paving the way for more effective and safer cancer therapies.